# GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

> **NCT02360111** · NA · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02360111
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360111, "GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02360111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*